Kyverna Therapeutics (KYTX) Receivables - Accured (2024 - 2026)

Kyverna Therapeutics' (KYTX) quarterly Receivables - Accured came in at $1.2 million in Q1 2026, up 100.0% on a QoQ basis from $600000.0 in Q4 2025.

Kyverna Therapeutics (KYTX) Receivables - Accured (2024 - 2026) Analysis & Trends

Kyverna Therapeutics (KYTX) has 3 years of Receivables - Accured data on file, last reported at $1.2 million in Q1 2026.

Quarterly Receivables - Accured changed N/A year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (changed N/A YoY) and the FY2025 annual result came in at $600000.0, changed N/A from the prior year.
Receivables - Accured grew to $1.2 million in Q1 2026, from $600000.0 in the prior quarter.
In the past five years, Receivables - Accured ranged from a high of $1.2 million in Q1 2026 to a low of $100000.0 in Q2 2024.
A 3-year average of $520000.0 and a median of $400000.0 in 2024 frame the typical range for Receivables - Accured.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acc. Int. Receivables (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Kyverna Therapeutics	505.26 Mn	505.26 Mn	-	1.70 Mn

Download Data